{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:30:27Z","timestamp":1786354227951,"version":"build-2736575974"},"reference-count":27,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,2,15]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A 5-domain composite Core Outcome Measures set for Severe Asthma (COMSA) has been introduced for evaluation of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The COMSA evaluation strategy was tested in a real-world study of 78 patients with severe asthma with blood eosinophilia taking mepolizumab. Exacerbations, oral corticosteroid (OCS) use, forced expiratory volume in 1\u2005s, Asthma Quality of Life Questionnaire score and Asthma Control Questionnaire-5 results were determined before treatment and 4, 12, 24 and 36\u2005months thereafter. Responses were quantified as the sum of changes in domains using both the relative CONFiRM (CompOsite iNdexes For Response in asthMa) scale, where exacerbations and OCS use are given most weight, and Modified Equal Weight Score (MEWS), where each domain gives equal weight. Both scales use identical cut-offs for degree of change within domains.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 1\u2005year, the MEWS scoring system classified 13% as non-responders, 28% as sufficient-responders, 40% as substantial-responders and 19% as super-responders. Using CONFiRM, the corresponding group stratification was 22%, 22%, 33% and 23%, respectively. Group assignments remained unchanged at 24 and 36\u2005months, for 66% of patients in COMSA-MEWS and 68% in COMFiRM. Baseline exhaled nitric oxide was highest among the super-responders, whereas other type 2 markers were similar across the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this first real-world application, the COMSA stratification assigned patients into distinct, graded responder groups that may be used in clinical research and management of severe asthma. Although patient-reported symptoms are given greater weight in COMSA-MEWS, the two algorithms performed similarly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01690-2025","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:15:25Z","timestamp":1774548925000},"page":"01690-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["COMSA-MEWS: a simple quantitative algorithm for determining response to biologics in severe asthma, tested in a real-world mepolizumab study"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-1265","authenticated-orcid":false,"given":"Valentyna","family":"Yasinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7116-6583","authenticated-orcid":false,"given":"Johan","family":"Kolmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6560-6124","authenticated-orcid":false,"given":"Maria","family":"Sparreman Mikus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-4052","authenticated-orcid":false,"given":"Lars I.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Sofie","family":"Lantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wallen-Niels\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0494-2690","authenticated-orcid":false,"given":"Apostolos","family":"Bossios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2078-0705","authenticated-orcid":false,"given":"Nikolaos","family":"Lazarinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana","family":"Tenselius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niclas","family":"Rydell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8113-0653","authenticated-orcid":false,"given":"Craig E.","family":"Wheelock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0619-7927","authenticated-orcid":false,"given":"Peter H.","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Brightling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4098-7765","authenticated-orcid":false,"given":"Andrei","family":"Malinovschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-6980","authenticated-orcid":false,"given":"Christer","family":"Janson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Mj\u00f6sberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbro","family":"Dahl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Erik","family":"Dahl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026081001451480000_12.4.01690-2025.1","doi-asserted-by":"crossref","first-page":"1150162","DOI":"10.3389\/fimmu.2023.1150162","article-title":"Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study","volume":"14","author":"Pavord","year":"2023","journal-title":"Front Immunol"},{"key":"2026081001451480000_12.4.01690-2025.2","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/biomedicines12050960","article-title":"Evaluation of clinical remission in best-performing severe asthmatic patients treated for three years with mepolizumab","volume":"12","author":"Bagnasco","year":"2024","journal-title":"Biomedicines"},{"key":"2026081001451480000_12.4.01690-2025.3","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/cea.14544","article-title":"Overcoming barriers to remission in severe eosinophilic asthma: two-year real-world data with benralizumab","volume":"54","author":"Jackson","year":"2024","journal-title":"Clin Exp Allergy"},{"key":"2026081001451480000_12.4.01690-2025.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00316-2024"},{"key":"2026081001451480000_12.4.01690-2025.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202311-2192OC"},{"key":"2026081001451480000_12.4.01690-2025.6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.anai.2024.09.023","article-title":"Identifying super-responders: a review of the road to asthma remission","volume":"134","author":"Mailhot-Larouche","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026081001451480000_12.4.01690-2025.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00819-2023"},{"key":"2026081001451480000_12.4.01690-2025.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.01.037"},{"key":"2026081001451480000_12.4.01690-2025.9","first-page":"35","article-title":"A possible explanation for non-responders, responders and super-responders to biologics in severe asthma","volume":"4","author":"Hyland","year":"2019","journal-title":"Explor Res Hypothesis Med"},{"key":"2026081001451480000_12.4.01690-2025.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00606-2022"},{"key":"2026081001451480000_12.4.01690-2025.11","doi-asserted-by":"crossref","first-page":"2400691","DOI":"10.1183\/13993003.00691-2024","article-title":"Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma","volume":"65","author":"Khaleva","year":"2024","journal-title":"Eur Respir J"},{"key":"2026081001451480000_12.4.01690-2025.12","first-page":"343","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"52","author":"Chung","year":"2018","journal-title":"Eur Respir J"},{"key":"2026081001451480000_12.4.01690-2025.13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02730-2021"},{"key":"2026081001451480000_12.4.01690-2025.14","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/all.15714","article-title":"Global initiative for asthma: 30\u2009years of promoting evidence-based asthma care","volume":"78","author":"Yorganc\u0131o\u011flu","year":"2023","journal-title":"Allergy"},{"key":"2026081001451480000_12.4.01690-2025.15","doi-asserted-by":"crossref","first-page":"e00138","DOI":"10.1016\/j.plabm.2019.e00138","article-title":"Development of an automated ImmunoCAP research assay for eosinophil derived neurotoxin and its use in asthma diagnosis in children","volume":"17","author":"Rydell","year":"2019","journal-title":"Pract Lab Med"},{"key":"2026081001451480000_12.4.01690-2025.16","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.9120-11ST"},{"key":"2026081001451480000_12.4.01690-2025.17","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00370-2023"},{"key":"2026081001451480000_12.4.01690-2025.18","doi-asserted-by":"publisher","DOI":"10.1136\/emermed-2017-206735"},{"key":"2026081001451480000_12.4.01690-2025.19","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1002\/sim.10268","article-title":"Transformed ROC curve for biomarker evaluation","volume":"43","author":"Yang","year":"2024","journal-title":"Stat Med"},{"key":"2026081001451480000_12.4.01690-2025.20","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.21105\/joss.02017","article-title":"ggalluvial: layered grammar for alluvial plots","volume":"5","author":"Brunson","year":"2020","journal-title":"J Open Source Softw"},{"key":"2026081001451480000_12.4.01690-2025.21","first-page":"36","article-title":"Fractional exhaled nitric oxide (","volume":"15","author":"Heffler","year":"2020","journal-title":"Multidiscip Respir Med"},{"key":"2026081001451480000_12.4.01690-2025.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.09.018"},{"key":"2026081001451480000_12.4.01690-2025.23","doi-asserted-by":"crossref","first-page":"100188","DOI":"10.1016\/j.jacig.2023.100188","article-title":"Predictors of persistent poor control and validation of ASSESS score: longitudinal 5-year follow-up of severe asthma cohort","volume":"3","author":"Tiew","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"2026081001451480000_12.4.01690-2025.24","first-page":"986","article-title":"Early reduction of","volume":"80","author":"Soendergaard","year":"2025","journal-title":"Allergy (Copenhagen)"},{"key":"2026081001451480000_12.4.01690-2025.25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S2213-2600(24)00250-9","article-title":"Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts","volume":"13","author":"Zein","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026081001451480000_12.4.01690-2025.26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5114\/reum\/190257","article-title":"Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus","volume":"62","author":"Suszek","year":"2024","journal-title":"Reumatologia"},{"key":"2026081001451480000_12.4.01690-2025.27","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"Gladman","year":"2002","journal-title":"J Rheumatol"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01690-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T08:45:28Z","timestamp":1786351528000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01690-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,10]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/23120541.01690-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01690-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}